Cargando…
Evaluating the usability and safety of the semaglutide single‐dose pen‐injectors through summative (human factors) usability testing
AIMS/INTRODUCTION: A single‐dose, shield‐activated pen‐injector for each of the three approved dose variants (0.25, 0.5 and 1 mg) of once‐weekly subcutaneous semaglutide has been developed to improve usability. This analysis presents findings from the summative usability testing process for the sing...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169358/ https://www.ncbi.nlm.nih.gov/pubmed/33034163 http://dx.doi.org/10.1111/jdi.13429 |